. 2021 Jul 6;11:606764. doi: 10.3389/fonc.2021.606764

Table 1.

Correlation between clinicopathological features and expression levels of miRNA in plasma with gastric adenocarcinoma.

Characteristic	Case	miR-936		miR-1306		miR-659-3P
Characteristic	Case	Median (range), △CT	p-vaule	Median (range), △CT	p-vaule	Median (range), △CT	p-vaule
Gender
Male	36	17.81 (15.87-20.48)	0.677	17.33 (15.18-19.54)	0.439	17.07 (14.24-20.10)	0.500
female	16	17.90 (15.69-19.65)	0.677	17.50 (14.53-19.96)	0.439	16.96 (13.39-19.27)	0.500
Age (years)
≤65	26	17.84 (16.22-20.48)	0.487	17.57 (15.52-19.96)	0.370	17.09 (13.39-20.10)	0.819
>65	26	17.81 (15.69-19.65)	0.487	17.32 (14.53-19.43)	0.370	17.07 (14.35-18.34)	0.819
Tumor size (cm)
<5	25	17.61 (15.87-19.72)	0.318	17.29 (15.18-19.96)	0.447	17.06 (13.39-20.10)	0.949
≥5	27	17.94 (15.69-20.48)	0.318	17.42 (14.53-19.43)	0.447	17.08 (14.24-19.10)	0.949
Differentiation
Moderate/ well	18	17.87 (15.56-20.48)	0.887	17.70 (14.53-19.96)	0.393	17.10 (14.35-20.10)	0.375
Poor	29	18.02 (16.31-19.59)	0.887	17.31 (16.22-19.54)	0.393	16.93 (13.39-18.34)	0.375
TNM stage
I, II	20	17.35 (15.69-19.72)	0.049	17.22 (14.53-18.50)	0.042	16.38 (13.39-20.10)	0.022
III, IV	32	17.99 (15.87-20.48)	0.049	17.45 (15.18-19.96)	0.042	17.42 (14.24-19.27)	0.022
Lymph node metastasis
Negative	14	17.26 (15.69-18.08)	0.004	17.01 (14.53-17.89)	0.004	16.07 (13.39-18.31)	0.002
Positive	38	17.99 (15.87-20.48)	0.004	17.59 (15.18-19.96)	0.004	17.42 (14.24-20.10)	0.002
Nerve invasion
Yes	29	17.88 (15.87-20.48)	0.543	17.70 (15.18-19.96)	0.072	17.39 (14.24-19.27)	0.085
No	23	17.64 (15.69-19.72)	0.543	17.32 (14.53-19.54)	0.072	16.76 (13.39-20.10)	0.085
Vessel invasion
Yes	34	17.91 (15.87-20.25)	0.538	17.59 (15.18-19.96)	0.023	17.46 (14.24-20.10)	0.001
No	18	17.69 (15.69-20.48)	0.538	17.08 (14.53-19.16)	0.023	16.31 (13.39-17.60)	0.001
Characteristic	Case	miR-3185		miR-6083		miR-6792-3P
Characteristic	Case	Median (range), △CT	p-vaule	Median (range), △CT	p-vaule	Median (range), △CT	p-vaule
Gender
Male	36	15.19 (10.92-18.43)	0.178	16.37 (13.85-19.73)	0.929	16.89 (14.56-20.03)	0.774
female	16	15.82 (14.17-17.26)	0.178	16.49 (14.29-18.08)	0.929	16.78 (15.00-17.89)	0.774
Age (years)
≤65	26	16.04 (10.92-18.43)	0.018	16.37 (14.47-19.73)	0.528	16.89 (14.56-20.03)	0.784
>65	26	15.13 (13.26-16.59)	0.018	16.55 (13.85-17.73)	0.528	16.78 (14.68-18.35)	0.784
Tumor size (cm)
<5	25	16.05 (13.26-18.43)	0.058	16.35 (13.85-19.73)	0.798	16.89 (14.56-20.03)	0.776
≥5	27	15.27 (10.92-17.57)	0.058	16.51 (14.29-18.32)	0.798	16.86 (14.68-18.35)	0.776
Differentiation
Moderate/well	18	15.60 (14.07-18.43)	0.710	16.38 (13.85-19.73)	0.810	16.49 (14.56-20.03)	0.504
Poor	29	15.93 (10.92-17.57)	0.710	16.41 (14.69-17.73)	0.810	17.02 (15.00-18.35)	0.504
TNM stage
I, II	20	16.28 (13.50-17.99)	0.016	16.12 (13.85-19.73)	0.011	16.86 (14.56-20.03)	0.296
III, IV	32	15.30 (10.92-18.43)	0.016	16.72 (14.47-18.32)	0.011	16.89 (14.68-18.35)	0.296
Lymph node metastasis
Negative	14	16.05 (13.50-17.57)	0.208	15.85 (13.85-17.23)	0.006	16.44 (14.56-17.52)	0.041
Positive	38	15.57 (10.92-18.43)	0.208	16.63 (14.47-19.73)	0.006	16.89 (14.68-16.89)	0.041
Nerve invasion
Yes	29	15.16 (10.92-18.43)	0.030	16.53 (13.85-18.32)	0.392	16.86 (14.68-18.35)	0.768
No	23	16.26 (13.50-17.99)	0.030	16.34 (14.29-19.73)	0.392	16.88 (14.56-20.03)	0.768
Vessel invasion
Yes	34	15.51 (10.92-18.43)	0.736	16.63 (13.85-19.73)	0.003	16.89 (15.16-20.03)	0.091
No	18	15.73 (13.50-16.74)	0.736	15.85 (14.29-17.64)	0.003	16.67 (14.56-18.25)	0.091

The bold values highlight statistical significance.